Advertisement

pp 1-7 | Cite as

Apparent Acetaminophen Toxicity in a Patient with Transaldolase Deficiency

  • Jasmine Lee-Barber
  • Taylor E. English
  • Jacquelyn F. Britton
  • Nara Sobreira
  • Jason Goldstein
  • David Valle
  • Hans Tomas Bjornsson
Research Report
Part of the JIMD Reports book series

Abstract

Transaldolase deficiency (MIM#: 606003) is a rare autosomal recessive defect in the pentose phosphate pathway. Affected individuals are at risk for progressive liver failure and hepatocarcinoma. In the transaldolase-deficient mouse model (Taldo1 −/− ), these hepatic complications are accentuated by oxidative stress related to acetaminophen administration. We report a 13-month-old transaldolase-deficient male who developed mild liver failure after receiving standard doses of acetaminophen during a febrile respiratory syncytial virus infection. He was admitted for respiratory distress with neutropenia and thrombocytopenia, but developed an enlarged nodular liver with accompanying splenomegaly and rising alpha-fetoprotein which peaked 2 weeks after acetaminophen exposure. Whole exome sequencing revealed compound heterozygous variants c.512_514delCCT (p.Ser171del) and c.931G > T (p.Gly311Trp) in TALDO1 (HGNC:11559), which encodes transaldolase (EC 2.2.1.2), a key enzyme in ribose metabolism. Urine polyols and plasma metabolomics confirmed the diagnosis of transaldolase deficiency. Studies on the Taldo1 −/− mouse model demonstrate acetaminophen-induced liver failure can be prevented by administration of the antioxidant N-acetylcysteine. Moreover, a published report showed treatment of a transaldolase-deficient patient with N-acetylcysteine was associated with a decrease in alpha-fetoprotein levels. After discontinuation of acetaminophen and prior to initiation of N-acetylcysteine treatment, our patient demonstrated resolving alpha-fetoprotein levels suggesting acetaminophen incited the liver failure.

Conclusion: Our observations support the conclusion from mouse model studies that transaldolase-deficient patients are uniquely sensitive to acetaminophen and should avoid this antipyretic. Recognition of this individualized toxicity and avoidance of acetaminophen are essential for management of these patients.

Keywords

Acetaminophen Actionable genetic disorders Pentose phosphate pathway Transaldolase deficiency Treatment of genetic diseases Whole exome sequencing 

Notes

Acknowledgments

The authors would like to thank the family for participating in this report. We thank Lisa Kratz at the Biochemical Genetics Laboratory at the Kennedy Krieger Institute for her reanalysis for specific metabolites in our patient’s sample. Dr. Bjornsson’s salary is covered by a NIH Director’s Early Independence Award (DP5OD017877). The Baylor-Hopkins Center for Mendelian Genomics is supported by a grant from the National Human Genome Research Institute, 1U54HG006493.

References

  1. Balasubramaniam S, Wamelink MM, Ngu LH et al (2011) Novel heterozygous mutations in TALDO1 gene causing transaldolase deficiency and early infantile liver failure. J Pediatr Gastroenterol Nutr 52(1):113–116Google Scholar
  2. Engelke UF, Zijlstra FS, Mochel F et al (2010) Mitochondrial involvement and erythronic acid as a novel biomarker in transaldolase deficiency. Biochim Biophys Acta 1802(11):1028–1035Google Scholar
  3. Eyaid W, Al Harbi T, Anazi S et al (2013) Transaldolase deficiency: report of 12 new cases and further delineation of the phenotype. J Inherit Metab Dis 36(6):997–1004Google Scholar
  4. Fenves AZ, Kirkpatrick HM, Patel VV, Sweetman L, Emmett M (2006) Increased anion gap metabolic acidosis as a result of 5-oxoproline (pyroglutamic acid): a role for acetaminophen. Clin J Am Soc Nephrol 1(3):441–447Google Scholar
  5. Grossman CE, Niland B, Stancato C et al (2004) Deletion of Ser-171 causes inactivation, proteasome-mediated degradation and complete deficiency of human transaldolase. Biochem J 382(2):725–731Google Scholar
  6. Hanczko R, Fernandez DR, Doherty E et al (2009) Prevention of hepatocarcinogenesis and increased susceptibility to acetaminophen-induced liver failure in transaldolase-deficient mice by N-acetylcysteine. J Clin Invest 119(6):1546–1557Google Scholar
  7. Hubbard TJ, Aken BL, Ayling S et al (2009) Ensembl 2009. Nucleic Acids Res 37(Database issue):D690–D697Google Scholar
  8. Oh JS, Choi JS, Lee YH et al (2016) The relationships between respiratory virus infection and aminotransferase in children. Pediatr Gastroenterol Hepatol Nutr 19(4):243–250Google Scholar
  9. Lek M, Karczewski KJ, Minikel EV et al (2016) Analysis of protein-coding genetic variation in 60,706 humans. Nature 536(7616):285–291Google Scholar
  10. Li H, Durbin R (2009) Fast and accurate short read alignment with burrows–wheeler transform. Bioinformatics 25(14):1754–1760Google Scholar
  11. Lipiński P, Pawłowska J, Stradomska T (2018) Long-term systematic monitoring of four Polish transaldolase deficient patients. JIMD Rep.  https://doi.org/10.1007/8904_2018_83
  12. McKenna A, Hanna M, Banks E et al (2010) The genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 20(9):1297–1303Google Scholar
  13. Perl A, Hanczko R, Telarico T, Oaks Z, Landas S (2011) Oxidative stress, inflammation and carcinogenesis are controlled through the pentose phosphate pathway by transaldolase. Trends Mol Med 17(7):395–403Google Scholar
  14. Qian Y, Banerjee S, Grossman CE et al (2008) Transaldolase deficiency influences the pentose phosphate pathway, mitochondrial homoeostasis and apoptosis signal processing. Biochem J 415(1):123–134Google Scholar
  15. Rodan LH, Berry GT (2016) N-acetylcysteine therapy in an infant with transaldolase deficiency is well tolerated and associated with normalization of alpha fetoprotein levels. JIMD Rep 31:73–77Google Scholar
  16. Sobreira N, Schiettecatte F, Boehm C, Valle D, Hamosh A (2015) New tools for Mendelian disease gene identification: PhenoDB variant analysis module; and GeneMatcher, a web-based tool for linking investigators with an interest in the same gene. Hum Mutat 36(4):425–431Google Scholar
  17. Thorell S, Gergely P, Banki K, Perl A, Schneider G (2000) The three-dimensional structure of human transaldolase. FEBS Lett 475(3):205–208Google Scholar
  18. Tylki-Szymańska A, Stradomska TJ, Wamelink MM et al (2009) Transaldolase deficiency in two new patients with a relative mild phenotype. Mol Genet Metab 97(1):15–17Google Scholar
  19. Verhoeven NM, Huck JH, Roos B et al (2001) Transaldolase deficiency: liver cirrhosis associated with a new inborn error in the pentose phosphate pathway. Am J Hum Genet 68(5):1086–1092Google Scholar
  20. Verhoeven NM, Wallot M, Huck JH et al (2005) A newborn with severe liver failure, cardiomyopathy and transaldolase deficiency. J Inherit Metab Dis 28(2):169–179Google Scholar
  21. Vernacchio L, Kelly JP, Kaufman DW, Mitchell AA (2009) Medication use among children <12 years of age in the United States: results from the slone survey. Pediatrics 124(2):446–454Google Scholar
  22. Zheng S-J et al (2015) Serum sphingomyelin has potential to reflect hepatic injury in chronic hepatitis B virus infection. Int J Infect Dis 33:149–155Google Scholar

Copyright information

© Society for the Study of Inborn Errors of Metabolism (SSIEM) 2018

Authors and Affiliations

  • Jasmine Lee-Barber
    • 1
    • 2
  • Taylor E. English
    • 3
  • Jacquelyn F. Britton
    • 2
  • Nara Sobreira
    • 1
    • 2
  • Jason Goldstein
    • 1
    • 4
  • David Valle
    • 1
    • 2
  • Hans Tomas Bjornsson
    • 1
    • 2
    • 5
    • 6
  1. 1.Department of PediatricsThe Johns Hopkins UniversityBaltimoreUSA
  2. 2.McKusick-Nathans Institute of Genetic MedicineThe Johns Hopkins University School of MedicineBaltimoreUSA
  3. 3.Russell H. Morgan Department of Radiology and Radiological ScienceThe Johns Hopkins University School of MedicineBaltimoreUSA
  4. 4.Pavilion PediatricsLuthervilleUSA
  5. 5.Faculty of MedicineUniversity of IcelandReykjavíkIceland
  6. 6.Landspitali University HospitalReykjavíkIceland

Personalised recommendations